Abstract
R (rituximab)-CHOP (cyclophosphamide, adriamycin, vincristin, and prednisone) is given to outpatients with CD20-positive lymphoma as a standard treatment. However, this regimen requires long-term infusion because of the necessity for monitoring the infusion reaction (IR) during R administration. In this study, pharmacological changes in anti-tumor agents were examined after the joint use of R and CHOP, and the possibility of concurrent administration of R and CHOP for outpatients was discussed. After combining antitumor agents with R, the binding capacity of R to the CD20 peptide and molecular changes in anti-tumor agents were measured by ELISA and LC/MS/MS-based analysis. At the same time, a pilot study involving concurrent administration of R and CHOP to patients with diffuse large B-cell lymphoma (DLBCL) was carried out after the first course of R-CHOP. After combining with either adriamycin or cyclophosphamide, the binding capacity of R to the CD20 antigen was equivalent to controls, and no molecular changes in adriamycin and cyclophosphamide were detected after combination with R. Twenty-one cases of DLBCL were treated safely with concurrent administration of R and CHOP. Twenty patients achieved complete remission after a full course of R-CHOP. The results indicated that long-term medication might not be necessary for outpatients treated with R-CHOP.
Keywords: Concurrent administration, KLH-CD20 peptide, LC/MS/MS, R-CHOP, Rituximab, lymphocytes, Prognostic Index, Antitumor agents, amino acids, adriamycin.
Anti-Cancer Agents in Medicinal Chemistry
Title:Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma
Volume: 12 Issue: 7
Author(s): Yoshihiro Yakushijin, Tomiko Tatsukawa, Takumi Yamaguchi, Takashi Egawa, Noriaki Hidaka, Keiko Ido, Katsuya Suemaru, Masaki Yasukawa and Hiroak Araki
Affiliation:
Keywords: Concurrent administration, KLH-CD20 peptide, LC/MS/MS, R-CHOP, Rituximab, lymphocytes, Prognostic Index, Antitumor agents, amino acids, adriamycin.
Abstract: R (rituximab)-CHOP (cyclophosphamide, adriamycin, vincristin, and prednisone) is given to outpatients with CD20-positive lymphoma as a standard treatment. However, this regimen requires long-term infusion because of the necessity for monitoring the infusion reaction (IR) during R administration. In this study, pharmacological changes in anti-tumor agents were examined after the joint use of R and CHOP, and the possibility of concurrent administration of R and CHOP for outpatients was discussed. After combining antitumor agents with R, the binding capacity of R to the CD20 peptide and molecular changes in anti-tumor agents were measured by ELISA and LC/MS/MS-based analysis. At the same time, a pilot study involving concurrent administration of R and CHOP to patients with diffuse large B-cell lymphoma (DLBCL) was carried out after the first course of R-CHOP. After combining with either adriamycin or cyclophosphamide, the binding capacity of R to the CD20 antigen was equivalent to controls, and no molecular changes in adriamycin and cyclophosphamide were detected after combination with R. Twenty-one cases of DLBCL were treated safely with concurrent administration of R and CHOP. Twenty patients achieved complete remission after a full course of R-CHOP. The results indicated that long-term medication might not be necessary for outpatients treated with R-CHOP.
Export Options
About this article
Cite this article as:
Yakushijin Yoshihiro, Tatsukawa Tomiko, Yamaguchi Takumi, Egawa Takashi, Hidaka Noriaki, Ido Keiko, Suemaru Katsuya, Yasukawa Masaki and Araki Hiroak, Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650138
DOI https://dx.doi.org/10.2174/187152012802650138 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Products Chemistry in Marine Ascidians of the Genus Aplidium
Mini-Reviews in Organic Chemistry The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment
Current Drug Targets Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Exploring Confluence-Related Signalling to Modulate the Expression of Oct4 – A Role in Facilitating Mouse Somatic Cell Reprogramming?
Current Stem Cell Research & Therapy Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Physicochemical Characteristics Of Novel P-Glycoprotein Inhibitors Of The Cage Dimeric 1,4-Dihydropyridine Type
Medicinal Chemistry Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Hereditary Breast Cancer in Sub-Saharan Africa
Current Women`s Health Reviews Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Radiation Induced Non-targeted Response: Mechanism and Potential Clinical Implications
Current Molecular Pharmacology Evaluation of Non-Coding RNAs as Potential Targets in Head and Neck Squamous Cell Carcinoma Cancer Stem Cells
Current Drug Targets Naturally Occurring NF-κB Inhibitors
Mini-Reviews in Medicinal Chemistry Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases
Current Vascular Pharmacology Potent Phosphatidylinositol 3-Kinase Inhibitors and Their Biology
Current Drug Discovery Technologies Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry Classical and Non-Classical Thyroid Hormone Intracellular Pathways Involved in T Lymphoma Growth
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives
Current Medicinal Chemistry Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies